Olmetec and Chronic kidney disease - a phase IV clinical study of FDA data

Summary:

Chronic kidney disease is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Synthroid, and have Hypopituitarism.

The phase IV clinical study analyzes which people have Chronic kidney disease when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Chronic kidney disease?

Chronic kidney disease is found to be associated with 1,825 drugs and 1,364 conditions by eHealthMe. Check the latest studies of Chronic kidney disease.

On Jul, 06, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 59 people (0.75%) have Chronic kidney disease.

Could Olmetec cause Chronic kidney disease?

Among these 59 people:

How long have people been on Olmetec when they have Chronic kidney disease? *

What is the gender of people who have Chronic kidney disease when taking Olmetec? *

female: 32.65 %
male: 67.35 %

What is the age of people who have Chronic kidney disease when taking Olmetec? *

What are other drugs people take besides Olmetec? *

What are other side effects people have besides Chronic kidney disease? *

Pain: 22 people, 37.29%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 19 people, 32.20%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 19 people, 32.20%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 17 people, 28.81%
Tendonitis (a condition that causes pain and swelling of tendons): 16 people, 27.12%
Weakness: 16 people, 27.12%
Cardiac Disorder: 16 people, 27.12%
Bone Disorder: 16 people, 27.12%
Hypersensitivity: 13 people, 22.03%
Cataract (clouding of the lens inside the eye): 8 people, 13.56%

What are the existing conditions these people have? *

Pain: 18 people, 30.51%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 18 people, 30.51%
Itching: 17 people, 28.81%
Wound: 16 people, 27.12%
Nodule (a growth of abnormal tissue): 16 people, 27.12%
Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 16 people, 27.12%
Secondary Adrenocortical Insufficiency (inadequate secretion of acth by the pituitary gland): 16 people, 27.12%
Tendonitis (a condition that causes pain and swelling of tendons): 16 people, 27.12%
Growth Hormone Deficiency: 15 people, 25.42%
Type 2 Diabetes: 8 people, 13.56%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Chronic kidney disease?

- Check whether Chronic kidney disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic kidney disease:

Chronic kidney disease (1,825 drugs)

Browse all the conditions that are associated with Chronic kidney disease:

Chronic kidney disease (1,364 conditions)

Related publications that referenced our studies

Aalaei-Andabili, S. H., Umer, M., & Keeley, E. C., "An Adult Woman With Stage 4 Chronic Kidney Disease and a Diffuse Rash", JAMA cardiology, 2019 Jan .
Aalaei-Andabili, S. H., Umer, M., & Keeley, E. C., "An Adult Woman With Stage 4 Chronic Kidney Disease and a Diffuse Rash", JAMA cardiology, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.